Headlines about Tokai Pharmaceuticals (NASDAQ:NVUS) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tokai Pharmaceuticals earned a news impact score of 0.17 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.5292173824392 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Tokai Pharmaceuticals (NASDAQ NVUS) opened at 4.07 on Tuesday. The firm’s market capitalization is $3.01 million. The company has a 50 day moving average price of $4.98 and a 200 day moving average price of $6.18. Tokai Pharmaceuticals has a 52-week low of $3.42 and a 52-week high of $18.83.

Separately, Zacks Investment Research raised Tokai Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th.

TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/tokai-pharmaceuticals-nasdaqnvus-receiving-somewhat-positive-news-coverage-report-finds/1488889.html.

Tokai Pharmaceuticals Company Profile

Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.

Receive News & Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.